An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
CytomX Therapeutics
Summary
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Description
The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify the maximum tolerated dose (MTD) of CX-2051 as monotherapy and as combination therapy (CX-2051 combined with bevacizumab). Part 2 (dose expansion) will further assess safety and tolerability as well as preliminarily assess antitumor activity of CX-2051 as monotherapy and/or combination therapy in indication-specific expansion cohorts.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue * Additional inclusion criteria may apply Exclusion Criteria: * Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated * Known active central nervous system (CNS) involvement by malignancy * Systemic ant…
Interventions
- DrugCX-2051
Investigational drug
- DrugBevacizumab
IV infusion
Locations (5)
- Sarah Cannon Research Institute at HealthONEDenver, Colorado
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Carolina BioOncology Institute, PLLCHuntersville, North Carolina
- Sarah Cannon Research Institute, LLCNashville, Tennessee
- START San Antonio LLCSan Antonio, Texas